Cardiogenic shock is a condition associated to high mortality rates. For decades, the treatment consisted of vasoactive drugs and intra-aortic balloon pump. Left ventricular assist devices have been recently introduced, however the high costs of these devices have prevented their widespread use in public and private health care systems. Our initial experience with TransCoreTM, a left ventricular assist device manufactured in Brazil, is reported in this study.
Myocardial infarction; Shock, cardiogenic; Heart-assist devices
